Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Related records

Trials (63)

• A Phase 1 Study of SKB571 in Subjects With Advanced Solid Tumors
• A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid Tumors
• A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities
• A Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvonralimab in Locally Advanced Cervical Cancer
• A Phase II Study of SKB571 in Patients With Lung Cancer
• A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants
• A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients
• A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC)
• A Randomized, Phase Ib, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SKB575 (HBM7575) in Participants With Asthma
• A Study of A166 in Patients With Advanced Solid Malignant Tumors
• A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
• A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy
• A Study of Intratumoral KL340399 in Patients With Advanced Solid Tumors
• A Study of KL130008 in Adults With Severe Alopecia Areata
• A Study of KL340399 in Patients With Advanced Solid Tumors
• A Study of KL590586 in Patients With Advanced Solid Tumors
• A Study of SKB107 in Advanced Solid Tumors With Bone Metastases
• A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)
• A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
• A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer